Europe Insulin Delivery Devices Market Outlook, 2028

Europe Insulin Delivery Devices Market Outlook, 2028

The European market for insulin delivery devices has been transformed by technological breakthroughs, rising diabetes prevalence, and a growing emphasis on personalised healthcare solutions. The landscape of insulin delivery devices in Europe has evolved significantly, with a focus on improving patient convenience, ensuring exact dosing, and minimising difficulties related to insulin administration. Diabetes cases have been steadily increasing in Europe, a trend that has been paralleled globally. According to the International Diabetes Federation (IDF), more than 50 million people (aged 20–79) in Europe have diabetes in 2021. This growth has increased demand for insulin administration systems that are both efficient and patient-friendly. Technological advancements have accelerated the development of sophisticated insulin delivery devices. The market has evolved dramatically, from basic insulin syringes and pens to more modern advancements such as diabetic insulin pumps, patch pumps, and continuous glucose monitoring (CGM) systems. These advancements aim to give more precise dosing, lessen the burden of injections, and improve diabetes control overall. Furthermore, increasing efforts from EU governments are expected to favour the European insulin delivery device industry. In recent years, European governments have launched various initiatives to raise awareness about diabetes and disease management while also investing heavily in the development of healthcare facilities. Manufacturers increasing R&D efforts to develop enhanced insulin delivery systems are fueling market expansion. The ageing population of Europe, as well as the rising prevalence of chronic diseases such as diabetes, have increased the demand for novel healthcare solutions. Diabetes prevalence varies throughout European countries, resulting in a wide range of needs and preferences in the insulin delivery device market. Device customization to meet these differences in patient demographics and preferences becomes critical, altering the market environment accordingly. In Europe, patient advocacy groups play an essential role in shaping healthcare laws and influencing patient decisions. These associations frequently advocate for greater access to advanced insulin delivery devices and educate patients and healthcare professionals. Their impact on legislation and public awareness campaigns has an impact on market dynamics and new technology uptake.

According to the research report, “Europe Insulin Delivery Devices Market Outlook, 2028,” published by Bonafide Research, the Europe Insulin Delivery Devices market is projected to reach a market size of more than USD 6.5 Billion by 2028. Europe works together with international regulatory agencies to harmonise standards and laws. Harmonisation with global criteria makes it easier for manufacturers to enter the market by easing the process of bringing insulin delivery devices to market across numerous areas. In Europe's healthcare sector, there is an increasing emphasis on patient-centred care. Insulin delivery device makers prioritise ease of use, portability, discretion, and reduced discomfort during insulin injection in their products. Devices that correspond with patient preferences and lifestyle choices are more likely to obtain market traction. An important driver is the integration of insulin delivery devices with digital health platforms, telemedicine, and mobile applications. Preference is given to devices that provide connectivity and compatibility with digital platforms for data monitoring, analysis, and remote patient management. Adoption of such connected devices is fueled by the move towards personalised healthcare and data-driven solutions. Personalised medicine is gaining popularity throughout Europe. Patients want treatment alternatives that are personalised to their own needs, preferences, and lifestyle, such as insulin delivery devices. Devices with customizable features, dosage flexibility, and adaptable features meet the growing demand for personalised solutions. The rising prevalence of diabetes among youngsters is also predicted to boost the European market for insulin delivery devices. Furthermore, children under the age of 15 are diagnosed with diabetes and given insulin for a variety of reasons, including genetic diseases. As a result, the market for insulin delivery devices is experiencing tremendous growth.

Based on report market is divided into six major countries Germany, United Kingdom, France, Italy, Spain and Russia. Among them Germany is expected to dominate the Europe insulin delivery devices market.

The German insulin delivery device market is a significant part of the larger medical device landscape in Europe, marked by continual innovation and an emphasis on enhancing patient experience and treatment efficacy. Rising diabetes prevalence, technological advancements in insulin delivery systems, increased diabetes management awareness, and favourable government policies supporting healthcare infrastructure are all driving growth in this market. Germany, being one of Europe's largest healthcare markets, has a robust infrastructure and significant healthcare spending, which encourages the insulin delivery device company to expand. Diabetes affects more than 8 million people in Germany, according to the German Diabetes Centre (DDZ) 2022. The number of people with type 2 diabetes in Germany will climb during the next two decades. According to DDZ researchers, more than 12 million people will have metabolic issues by 2040. Germany is a developed country with excellent healthcare. Continuous glucose monitoring and insulin infusion pumps are being adopted at a faster rate in Germany than in other rising markets. Furthermore, reimbursement and pricing policies are carefully enforced, hastening the adoption of new and advanced technology. In Germany, medical equipment, notably insulin delivery devices, is subject to stringent regulations. The country's regulatory authorities, such as the Federal Institute for Drugs and Medical Devices (BfArM), ensure the safety and efficacy of these devices, encouraging trust among both healthcare professionals and patients.

Based on product market is segmented into insulin pens, insulin pumps, insulin pen needles, insulin syringes and others insulin delivery devices(insulin transdermal patches, insulin inhalers, insulin jet injection). The market is majorly dominated by insulin pens with significant market share.

Insulin pens provide unprecedented convenience and ease of use, making them popular among diabetic patients. Their simple and intuitive form enables easy handling and discrete administration, avoiding the need for vials, syringes, and calculating insulin doses. This ease of use improves patient adherence to insulin therapy, especially for individuals who require numerous daily injections. Insulin pens are extremely convenient for people who lead active lifestyles because of their small size and portability. Their elegant, pen-like appearance allows for discrete administration, allowing users to inject insulin in a variety of contexts without calling attention to them. This portability corresponds to modern lives, allowing patients to control their illness while on the go, at work, or in social settings. Insulin pens provide precise dosing, ensuring appropriate insulin dosage delivery even in small increments. This precision is critical in diabetes care because it allows for precise modulation of insulin levels based on individual needs. Pens' dial-up mechanics and clear dosage indicators give consumers confidence in proper dosing, which contributes to better glycemic management. Insulin pens are available for rapid-acting, short-acting, intermediate-acting, and long-acting insulins. This adaptability enables patients to select pens that are matched to their unique insulin requirements. Furthermore, the dosage flexibility provided by pens allows for varying insulin doses, giving alternatives to both low-volume and high-volume users.

In terms of end user market is divided into home care, hospitals and clinics and others. Home care end user segment is expected to lead the market of Europe. Based on indication market is bifurcated into diabetes, pregnancy, cardiovascular disorders & hypertension, respiratory diseases, hearing disorders, cancer, movement disorders, wound care and other indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV).

The trend towards patient-centred care has been critical in pushing the adoption of insulin administration devices in home care settings. Patients increasingly want greater autonomy and control over their healthcare, seeking solutions that enable self-management of chronic illnesses such as diabetes. Insulin delivery devices, particularly user-friendly choices such as pens and advanced injection systems, enable patients to administer insulin dosages themselves, fostering independence and active engagement in their treatment. Insulin administration systems combine ease with the comfort and familiarity of home care settings. Patients prefer to manage their insulin medication in the privacy and comfort of their own homes, avoiding repeated visits to healthcare facilities. The portability and convenience of using devices such as insulin pens allow for discreet and hassle-free administration, boosting adherence to treatment regimens without compromising lifestyle or daily routines. Diabetes is a major public health concern in Europe, affecting a large proportion of the population. According to the International Diabetes Federation (IDF), millions of people in Europe have diabetes, and the number is growing. Diabetes's sheer prevalence needs appropriate control, fueling demand for insulin delivery devices. Personalised medicine and patient-centred treatment are becoming increasingly important in Europe's healthcare sector. Diabetes management does not require a one-size-fits-all strategy; rather, it necessitates customised treatment solutions. Insulin delivery devices are critical in providing patients with options that match their preferences, lifestyle, and treatment goals, contributing to the market dominance of diabetes-related equipment.

Companies Covered in this report:

Novo Nordisk A/S , Sanofi S.A., Eli Lilly and Company, Medtronic plc , Terumo Corporation, Becton, Dickinson and Company, Insulet Corporation, Biocon Limited , Wockhardt Ltd., B. Braun Melsungen AG, Medline Industries, LP.

Considered in this report:

• Geography: Europe
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• Europe Insulin Delivery Devices market Outlook with its value and forecast along with its segments
• Country-wise Insulin Delivery Devices market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country covered in the report:

• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia

By Product:

• Insulin Pens
• Insulin Pumps
• Insulin Pen Needles
• Insulin Syringes
• Others Insulin Delivery Devices(Insulin transdermal patches, Insulin inhalers, Insulin jet injection)

By End User:

• Home Care
• Hospitals & Clinics
• Others

By Indication:

• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Respiratory Diseases
• Hearing Disorders
• Cancer
• Movement Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

The approach of the report:

This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations, and organisations related to the Insulin Delivery Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.

***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.